2689-37-4

Basic information

• Product Name: N,N-diethyl-2-fluoro-4-nitroaniline
• Synonyms: N,N-diethyl-2-fluoro-4-nitroaniline
• CAS NO: 2689-37-4
• Molecular Weight: 212.224
• Mol File: 2689-37-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N,N-diethyl-2-fluoro-4-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-diethyl-2-fluoro-4-nitroaniline(2689-37-4)
• EPA Substance Registry System: N,N-diethyl-2-fluoro-4-nitroaniline(2689-37-4)

Safety Data

• Hazardous Substances Data: 2689-37-4(Hazardous Substances Data)

Upstream product

• 369-34-6 3,4-difluoronitrobenzene 
• 109-89-7 diethylamine 

Downstream Products

• 83800-33-3 N¹,N¹-diethyl-2-fluorobenzene-1,4-diamine 
• 1229016-79-8 2-[(3-fluoro-4-diethylamino)phenylamino]-6-chloro-3-nitropyridine 
• 1229015-19-3 2-[(3-fluoro-4-diethylamino)phenylamino]-6-(methylamino)-3-nitropyridine 

Relevant articles and documents

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME

The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyr